Bristol Myers Squibb (BMY)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
$66.82-1.87%
Close 2026-09-04 · 1-day change
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
Intact: The reason to own it still holds.
Bristol Myers Squibb grows revenue around $46.6 billion in 2026. Earnings per share reach about $6.20. Profit margins stay near 69.5%. The company benefits from strong drug pipelines and partnerships.
Revenue growth could slow below analyst expectations. Profit margins might compress due to rising costs. Innovation risks and competition could hurt future earnings.
The market prices in about -3% revenue growth and the stock trades roughly 11% below our fair value near $65. We see potential for modest growth and margin stability above these expectations.
Breaks if: EPS falls below $5.90 in FY26
Breaks if: gross margin falls below 67% in FY26
Breaks if: major clinical trial failures or partnership dissolutions
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
BMY represents a durable compounder with a stable management team and a focus on growth through its portfolio. The current thesis remains intact due to consistent financial performance and a commitment to innovation.
The market currently prices BMY as cheap compared to its peers, with a low expectations gap. This suggests that investors may not fully anticipate the potential for continued growth in the company's earnings.
BMY's fundamentals are likely to remain strong, driven by growth in its portfolio and stable cash flow. However, there is a low probability of missing earnings expectations, though past performance shows some volatility.
The long-term thesis hinges on BMY maintaining its growth trajectory and the overall healthcare sector's performance. Key factors include the performance of sector leaders and the company's ability to avoid cutting guidance.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company raised its full-year revenue and EPS guidance for 2026. However, a revived lawsuit could impact financial stability and delay drug pipeline advancements.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: annual revenue falls below $45 billion in FY26
In the next 1 to 3 years, BMY's prospects look promising, supported by strong management and a favorable sector backdrop. Not investment advice.